Genentech, UC in Talks to Settle Lawsuit
- Share via
Genentech Inc. and the University of California are in talks to settle a nine-year lawsuit over claims that the world’s No. 2 biotech company violated patents in developing growth hormone drugs, people familiar with the situation said. A resolution would avoid bringing the matter to a second trial. A six-week trial ended in June with a deadlocked jury. South San Francisco-based Genentech is majority-owned by Swiss drug maker Roche Holding. UC has sought $1 billion in damages related to royalties it believes it should have gotten from the sale of the growth hormones Protropin and Nutropin, two of Genentech’s top-selling products.
*
Guide to Our Staff: Need to reach Business section reporters or editors? A guide to the section’s staff can be found at http://161.35.110.226/bizstaff.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
